Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Yes. Welcome, everybody, to our Q3 report presentation. As usual, Stefan and I will go through what has happened during that time period. Stefan will cover the financials. I will handle the rest. And without any further ado, I will start the presentation with our forward-looking statement. I would like to start with a quick summary. What has happened? Events in the third quarter, as well as the events after the end of the period. And obviously, one very important event during the third quarter was our prior authorization in the portfolio to really focus on the two lead programs, with all the resources doubling down on the two most advanced programs, BI-1808 and BI-1206. And I will come back with a little bit more detail later. And then the other thing was that there was a change in the board. Vincent Ossipow, who has been with us for many years. Stepped down for priority reasons. And I think this is a very normal change. And as I said, he has been with us for almost ten years. Following the end of the period, the most important event was the initiation of the Phase IIa trial for 1206 in advanced or metastatic non-small cell lung cancer and uveal melanoma. And this is a first-line study. So, it's extremely exciting. So this is based on the promising data that we have generated in heavily pretreated patients. We showed that data to Merck, and they agreed that we could proceed with the combination trial in first-line non-small cell lung cancer and uveal melanoma. It's extremely exciting. Then, we had some data presentations. So the phase one clinical data for BI-1910, our TNFR2 agonist for the treatment of solid tumors. It will be presented at CDC in 2025. And then together with Transgene, we presented translational data and updated clinical results on the armed oncolytic virus program BT-001. That was at ESMO this year. So coming back to our prioritization, what you see here on this slide is the portfolio. And that's still our portfolio. So what we're doing now, of course, is prioritizing the two lead programs. That makes a lot of sense because 1808 and 1206 are now in advanced clinical studies, which means they are in phase two. These are two assets that are active in both liquid and solid tumors, and they are first in class. And the other program. So 1910, our second TNFR2 program, as well as 1607. Our second NT FcγRIIB program. They are now paused, and then the BT-001 program in solid tumors, which is basically the oncolytic virus containing our anti-CTLA-4 antibody, is continued. Based on investigator-initiated trials. We're really now focusing and doubling down on 1808 and 1206. And on this slide, you have the summary of what I have partly already said. In August 2025, we announced the decision to focus on our two most advanced programs, BI-1206 and BI-1808. And what I always say, this is obviously an unfair competition, because 1910 and 1607 might also be interesting, but they're much, much earlier. They're still in phase one dose escalation. And of course, 1206 and 1808 are already in phase two. The earlier clinical programs, as I already have said, will be paused after a wind-down period to complete the ongoing trial activities because we want to pause it in a way that we can reuse it either ourselves or with a partner. And also the underlying research activities are now streamlined to better support the two lead clinical programs. 1206 and, uh, 1808. So this slide would show you the prioritized portfolio, where we have basically 1808 and 1206, as I already said. So, 1808 is our TNFR2 program, which is running as a single agent as well as in combination with pembrolizumab in solid tumors and T-cell lymphomas. And both. 1206, our lead entity FcγRIIB program, is running in combination for non-Hodgkin lymphoma with rituximab and acalabrutinib. And in solid tumors with pembrolizumab. It's already been mentioned that this trial has been initiated, focusing on first-line non-small cell lung cancer and uveal melanoma. Just for completeness, on the right-hand side of this slide, you see our partners. Whenever we use Pembro, we do so under a supply and collaboration agreement with Merck. Uh, and whenever we use Acalabrutinib, this is under a similar agreement with AstraZeneca. And that is something very interesting because those are two potential partners that are already sitting at the table in a way. And then, of course, the last name is our longstanding partner in China, CASI. They have exclusive rights for the BI-1206 program in China, Hong Kong, Macau, and Taiwan. So, more detailed information around the programs, just to recap where we stand. As I already mentioned, BI-1808 is developed for T-cell lymphoma as well as solid tumors, both as a single agent and in combination. Here on this slide, we present the data from June this year. Basically, the monotherapy is showing really promising strong efficacy in CTCL and PTCL. We had 100% disease control in nine evaluable patients, with complete responses, partial responses, and stable disease. And of course, it's important to remember or to remind everybody that these patients are heavily, heavily pretreated. But we also have on top of that two evaluable patients in CTCL, which is an even more severe form of T-cell lymphoma, where we had one partial response and one patient with stable disease. It's important to note that the treatment is well tolerated with only mild to moderate adverse events. So basically, no toxicity issues. And also, very importantly, immune activation was observed. It was observed early on, with depletion of regulatory T cells and the influx of CD8 positive T cells into the skin lesions, which is very, very important. And then to remind everybody, we have orphan drug designation for PTCL and fast track designation for CTCL. So what is next? This will be actual additional data already this year. Additional phase two data. I think we guided the market that this will come next year, but we have good progress and we will already have an update this year. Then going into the other parts of the 1808 program, which is the solid tumor study. We have established single-agent activity, which is really something exciting because antibodies against TIGIT or LAG3 have never achieved that. We observed complete responses, partial responses, and actually had 11 out of 26 evaluable patients showing a response. And obviously, again, we have very, very heavily pretreated patients. And again, I emphasize this is single-agent activity with a very good safety profile. And then what we also presented at ASCO in June 2024 is some initial activity or data that we had in the combination, which of course was a little bit later since we started the single agent clinical development first and then followed on with the combination with Pembrolizumab. And here we have already guided the market. So the phase two pembrolizumab combination data in solid tumors. That will also be a first data point or second data point, actually, after the ASCO in 2024 for this year. So basically for BI-1808, there will be an update on monotherapy for CTCL. And as promised, we will provide the update on the combination with pembrolizumab in solid tumors this year. Then I switch to our anti-FcγRIIB program with BI-1206 that we developed in non-Hodgkin's lymphoma and solid tumors, starting with the data that we presented this year. That is the combination with acalabrutinib and rituximab. We had 100% disease control in the first eight patients out of 30 patients in the complete trial. Complete responses, partial responses, and stable disease demonstrate a good overall response rate. And again, this treatment has been well-tolerated with no safety and tolerability concerns. And of course, it's important to note that BI-1206 is administered subcutaneously. This means we have a very convenient and safe profile for this combination, making it a highly competitive option in the evolving non-Hodgkin lymphoma treatment landscape. We have orphan drug designation. And also here we have an update because we guided the market that we will come out with the next data set during the first half of next year. And that will already happen this year. So, it is also very exciting, which means this is already the third update. That will be in addition to what we had already guided the market for. On the other hand, regarding the solid cancer study, you might remember the very strong data we have shown, targeting patients who no longer respond to anti-PD-1 or anti-PD-L1 therapies, and who have received two or more immuno-oncology treatments. Two or more I-O treatments. And we saw complete responses and partial responses. We showed that data to Merck, and they agreed that we can move into the first line. And that's what we have already started. So there was a press release a week or two weeks ago, and we're focusing on advanced metastatic non-small cell lung cancer and uveal melanoma. And we're focusing on sites in Georgia, Germany, Poland, Romania, Spain, Sweden, and the US. And here, as we have already guided the market. So we will have a first glimpse of the data during the second half of next year. Then very briefly on CTLA-4, even though that is not our core focus, but it is worth mentioning since it happened. So that was presented at ESMO. We could show that the BT-001 injection combination with pembrolizumab was well tolerated, showing positive local abscopal and sustained anti-tumoral activity in injected and non-injected lesions. Long-lasting partial responses were observed, and the overall data supports further development across a range of solid tumors. Tumor types to improve responses to cancer immunotherapies. And the next step here is the evaluation of BT-001 via the investigator-led trial in an early-stage setting. What I already have mentioned, and then I hand over to Stefan for the financial overview.
Thanks, Martin. So that means we have a very convenient and safe profile of this combination, which is a highly competitive option in the evolving non-Hodgkin lymphoma treatment landscape. I will present the financial overview for Q3 in the nine-month period, January to September. All amounts are in SEK million. Unless otherwise mentioned, net sales were 3.3 million in Q3 2025, compared to 12.8 million in Q3 2024. That decrease is related to the production of antibodies for customers. It was 9 million lower in 2025. Net sales for January to September 2025 were 223 million. For the same period in 2024, net sales were 23 million. That's an increase of 200 million. The increase is mainly related to the $20 million payment. When XOMA royalty acquired future royalty rights to Mezagitamab. Prior to that, a $1 million milestone was received in the collaboration with XOMA. Operating costs increased from 120 million in Q3 2024 to 137 million in Q3 2025. That's an increase of 17 million. We had significantly higher costs in BI-1206 and higher costs for BI-1808, and somewhat lower costs in other areas. By 19.10. And we also had higher personnel costs from January to September in Q3 2025. The increase of operating costs was 77 million, from 369 million in 2024 to 446 million in 2025. During the period, we had significantly higher costs in Beer12.6 and Beer8.8 and increased costs in BY-1910, and personnel costs in 2025 were considerably higher compared to 2024. The result for Q3 2025 was -129.2 million, and the result for January to September was -207.1 million. Liquid funds and current investments. End of September 2025 amounted to a total of 690 million. Over to you, Martin.
Thank you. Stefan. So then, at the end, I would summarize again the key catalysts for the remaining 2025 and 2026. I think I mentioned it already, but it's always good to go over this again. And you see it here on the slide. Since there have been some changes, we originally guided the market that we would have a data update for age and weight in solid tumors, in combination with pembrolizumab. In addition to that milestone, we will also update on BI-1808, additional phase 2 single agent data this year, as well as additional phase 2 data with rituximab and acalabrutinib for 2026, in non-Hodgkin lymphoma. Otherwise, for next year. So we'll have the phase 2 data with pembrolizumab in TCL for BI-1808. And then, of course, there will be additional triplet data. So, for BI-1206 in non-Hodgkin lymphoma, in combination with rituximab and acalabrutinib. And then in the second half, we will have the first data update regarding 1206 first line in solid tumors. And that will be the first readout during the second half of next year. So I stop here and open up for questions.
If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Sebastian van der Schoot from Kempen. Please go ahead.
Hi everyone. Thank you for taking my questions. There appears to be a lot of data still coming in 2025, and I just wanted to know whether you can provide a little bit more color on the different readouts. Maybe starting with the triple regimen for 1206. I noticed on the slide that it mentioned disclosed data on the first eight out of a total of 30 patients. Does that mean that we will get an update on the total patient number of 30 with the next one? And how long will the follow-up be for that particular readout?
If you wish to withdraw your question, please dial the pound key on your telephone keypad. So, for that. Hi, Sebastian. For that program, we have BI-1206, which is in combination with acalabrutinib and rituximab. So basically, we now have more patients. We'll have an update on the overall response rate. We'll have an update on the complete response rate. So, basically an update on the study as it's progressing at the moment.
If you wish to withdraw your question, please dial the pound key on your telephone keypad. Got it. And could you also provide us a little bit more color on the 1808 readouts in CTCL. And for the combination with pembrolizumab in solid tumors? Like, how many more patients will we get? Is it going to be like a handful, or is it going to be a substantial update?
For 1808, I'm just repeating because you were interrupted due to some background noise, wherever you are. Sebastian. So for 1808, this is, of course, monotherapy in T-cell lymphomas. Right? So no combination. And because the combination will be next year as already guided. So this is an additional update that we have. As you might remember. So the single agent part or escalation has been completed. And that will basically entail further analysis of that data and provide an update on where we are regarding the different complete responses, partial responses, and stable diseases. And there is also quite some interesting information on the translational side.
So, this is an additional update that we have. Got it. Thank you so much, Martin.
You're welcome. Sebastian.
The next question comes from Richard Romanus from Redeye. Please go ahead.
Hello. Good afternoon. I will continue where Sebastian left off. Could you remind us about the next steps for both attenuating T-cell lymphoma and BI-1206 in normal lymphoma in 2026?
Yes. So basically, I will start with the 2808 first, as I mentioned to Sebastian. So the single agent part, the escalation, etc. So the single agent part, the escalation, has been completed. So that is finished. What we have already started is the combination with pembrolizumab. And the reason why we do this is to see whether it can be even better. So, as you remember. So the single agent data is very impressive. But nevertheless, we also wanted to test the combination. And that is currently ongoing. Uh, and the update on that data will then be at some point next year. Uh, and then for BI-1206, the update that is coming now is basically further progress of the study. Uh, and then next year, we will, of course, finish the study with the 30 patients. It depends on the data a little bit where we move. But we already had discussions with the regulators such that we potentially could proceed at some point. A pivotal study. But as you know, this is something that we want to do in a collaboration. So basically, what we're doing is to really finish up with the 30 patients, which will happen during next year. And hopefully with a very strong overall response rate plus a very high rate of complete responses. And we're quite optimistic that we can achieve that.
I was thinking about your potential license partners. You're going to get some data in the triple combination now and some more in early 2026. While the data in combination with pembrolizumab in non-small cell lung cancer and uveal melanoma will be available around one year later. So what about a hypothetical question? What if AstraZeneca is very interested? What are the options for MSD Merck then?
Yeah, it's a very interesting question, obviously. First of all, maybe a slight correction. The first data that we'll have for the 1206 Pembro combination will be during the second half of next year. So it's not a year later because I think we'll have, during the first half, a further update or what we have actually guided. Now it's mid next year on the triplet. So I think we might even have, and as you know, Merck, as well as AstraZeneca, they don't have any rights. But they see the data a little bit earlier. So what we're doing now is pushing really hard on the 1206 pembro combination as much as we can, such that we might already have some interesting data that are not in the market yet, but that Merck will see, since they are following us closely. That could then trigger interesting discussions. So that might be enough. Let's say AstraZeneca would make the move. If Merck would see something that is interesting bubbling up, they might be able to counter. I think I will use the opportunity here to update or to remind everybody. So with 1206, obsolete subcu. And if you only see, let's say, a 10% increase in responses to Keytruda as first-line treatment, this is, of course, a very interesting development for Merck, because Merck's Keytruda has just been approved as a subcutaneous formulation. So you could then really think of co-formulating Keytruda Subcu and 1206 Subcu into one injection, basically. And that could be something very, very interesting. And coming back to your question. So I think if we see initial data and Merck sees it rather early, they might still be able to react in case AstraZeneca comes forward and is interested in a collaboration.
And what about an interest from AstraZeneca in combining the H156 with Imfinzi or Durvalumab versus checkpoint inhibitors? Yes, absolutely. That might be.
Absolutely. That could be another option. The thing is, I get this question a lot, and some people think AstraZeneca might, if they're interested, collaborate on non-Hodgkin lymphoma and work on solid cancers. But if either party is interested in doing that, then they will probably opt for the full program, even if they have some specific interest. So AstraZeneca could absolutely consider it if they think. 1206 is interesting enough for them to consider collaboration, and they might also consider it for other applications besides non-Hodgkin lymphoma. Absolutely.
Okay, thanks. Then I just have one more financial question. Are we going to see any more results of the cost-cutting measures introduced recently? And what type of burn rates could we expect going forward?
I think you could say, right now, for the first three quarters, we have 446 million. So, you could extrapolate that through the year to a little bit less than 600. And that will go down a little bit next year.
And coming back to your question. And coming back to your question. Thanks for taking my questions.
Thank you, Richard.
The next question comes from Oscar Hafen, Lam from Stiefel. Please go ahead.
Hi. Thanks for taking my questions. My first question would be on the readout coming out earlier than last communicated. Could you just give us some granularity on the reasons behind? Is it simply due to faster recruitment than you initially planned?
It's basically due to progress on different fronts. Recruitment is obviously one part of it. The interest in both studies is very high. Recruitment is progressing very well. And then, of course, you have better progress than we originally planned. So that's the main reason. That's the main reason.
It's basically due to progress on different fronts. It's basically due to progress on different fronts. It’s basically due to progress, you know, on different fronts. And then the second question on the 1206 triplet combo data, what is the next data? Include patients that are treated with a higher dose of 1206 compared to the last updates. I'm thinking, you know, the 225mg compared to 150mg that was mainly used in the preliminary data.
Yes. So basically, the data that you will see is a continuation of the data that we already presented earlier this year. It will be the same dose, just with a higher number of patients.
It's basically due to progress on different fronts. Go ahead. It's basically due to progress on different fronts.
It's basically due to progress, you know, on different fronts. Oscar.
The next question comes from Dan, actually from Pareto Securities. Please go ahead.
Hi, Martin, and thank you for taking my question. Just one follow-up on the previous one.
So in May of this year, you showed that all eight patients in the study demonstrated a response in terms of reduction.
Patients in the triplet combo in NHL had shown a reduction in the sum of the target lesions. Even the stable disease ones were moving towards a response.
And I'm just wondering, at the end of this year, is that going to be another interim readout, or will it be of the full 30 patients, or will we get the full one then still in the first half of next year? Yes. Thank you. Is there a possibility to go into Phase 3 as a single agent for 1808, in CTCL? Thank you.
Yes. Starting with 1206 first, the full cohort of 30 patients will be reached at some point next year. I think roughly by mid next year. So what we have now is not the full 30 patients yet, but significantly more than what we had shown in May. Yes. Uh, and on 1808. So yes, absolutely. The plans and what we have discussed with the regulatory are for a single-agent pivotal study. And I don't have the slide here in the deck, so I just have to memorize what we will do? So, as I mentioned earlier. So we're currently running the combination with Pembrolizumab. In parallel, we start with dose optimization and then also prepare for the pivotal study, ensuring that those plans remain the same. We potentially could start a pivotal study for monotherapy as a first-line treatment in 2027.
Okay. Thank you very much.
Thank you, Dan.
The next question comes from Arvid Nicotra from Denbigh Carnegie. Please go ahead.
Good. Good afternoon and thanks for taking my questions. So good to see the planned readouts being ahead of schedule. So first off, on 1206 and the triplet, you seem pretty upbeat, Martin, about response rates being able to move up as patient numbers increase. So can you share anything about your expectations for the readout plan before the end of the year? And what would make this readout live up to expectations? And secondly, you should have a pretty substantial dataset on the doublet. And we've seen some really nice, long-lasting responses. And we've also seen the duration of complete responses. But can we also expect you to disclose the median duration for all responses? Is this data mature enough? Essentially. I'll start there. Thank you.
Yes. But can we also expect you to disclose the median duration for all responses? For the data package, what we're expecting is basically, as I already mentioned earlier, the overall response rate, which should be, and that's our target, above 75%. And then the other point is a very high ratio of complete responses. So that is what we hope to present to the market. And then, just remind me of the second part of your question.
Certainly. So that was on the median duration of response for the doublet and whether or not that data is mature enough to present.
Yeah. So what we have, we can present, but obviously. The study did not start that long ago. But, you know, it looks like what we have seen, although the study is still relatively young, the data is preliminary. So those patients that were in complete response are still in complete response. So now this is more than three years for some of those patients. But obviously, we don't have the same duration data with the triplet combination because that just started less than a year ago. But we can see that the responses we get are enduring. Right. But it's still early days.
But can we also expect you guys to disclose the median duration for all responses? Thanks, Martin.
Thank you.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Yes. Thank you everybody for participating and also for the good questions. We are, of course, happy and excited that we can update the market earlier than we projected around BI-1808, single agent CTCL, and BI-1206 in Non-Hodgkin Lymphoma. I think this is very good and shows the interest in the study regarding the sciences that are involved. And, of course, this is driven by good data, obviously. Otherwise, we wouldn't have that progress. And then also next year, I think we are really zoning into a very interesting phase of the company because then we have more mature data, which should drive partnering and or financing. I'm really looking forward to that, especially partnering. So I think I will conclude with those words. I don't know, Stefan, do you have any final comments from your financial perspective?
No further comments.
Thank you everybody for participating and also for the good questions. Then I think we can close the meeting. Thank you very much and talk to you soon.



















